Dr. Teruko Ishizaka, Who Advanced Allergy Treatment, Dies at 92

She and her husband identified an antibody that triggers wheezing and rashes. Monitoring it can help prevent and remedy allergic reactions.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Allergies Ishizaka, Teruko (1926-2019) Deaths (Obituaries) Asthma Hay Fever Ishizaka, Kimishige (1925-2018) Tokyo (Japan) La Jolla (Calif) Doctors Source Type: news

Related Links:

Conclusions Current allergic rhinoconjunctivitis is related to enhanced disability caused by headache in childhood migraine.RESUMO A enxaqueca é condição comum na população pediátrica e causa significativo impacto na qualidade de vida. Doenças atópicas estão entre as principais morbidades associadas. Objetivo Teorizamos que a rinite alérgica possa agravar a enxaqueca na população pediátrica. Métodos Este estudo transversa l avaliou consecutivamente 90 pacientes pediátricos (46 crianças de 6 a 12 anos; 44 adolesce...
Source: Arquivos de Neuro-Psiquiatria - Category: Neurology Source Type: research
Conclusions Our results suggest that current allergic rhinitis, allergic rhinoconjunctivitis, and seasonal allergic rhinitis are not related to headache disability in adults with episodic migraine.RESUMO A migr ânea é uma condição dolorosa crônica com fisiopatologia complexa. Apesar de disfunções imunológicas já terem sido ligadas à migrânea, poucas foram as tentativas, na literatura, de se avaliar a possibilidade da rinite alérgica como um fator agravante da migrânea em adultos, tornando a qu estão ainda não esclarecida. O...
Source: Arquivos de Neuro-Psiquiatria - Category: Neurology Source Type: research
Conclusions: Patients with PA-EA had greater HCRU, healthcare expenditures, and lower productivity compared with those patients with PA-NEA. These results highlight the burden of atopy in patients with persistent asthma and underscore the importance of allergic endotype identification for more vigilant disease management. PMID: 31264894 [PubMed - as supplied by publisher]
Source: Journal of Asthma - Category: Respiratory Medicine Tags: J Asthma Source Type: research
Publication date: July–August 2019Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 7, Issue 6Author(s): Sarah Diver, Richard J. Russell, Christopher E. BrightlingEosinophilic airway inflammation is observed in 30% to 50% of chronic cough sufferers. It is a common feature of asthma and upper airway cough syndrome, and it is required in the diagnosis of nonasthmatic eosinophilic bronchitis. Our understanding of the mechanisms underlying allergic and nonallergic eosinophilic inflammation have evolved tremendously in the last 2 decades, but the cause of this inflammation in any individual is of...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Allergic rhinitis (AR) and asthma both lead to significant morbidity and healthcare usage in the United States.1,2 Pollens contribute to increased AR symptoms and asthma exacerbations. Ragweed (Ambrosia spp) and other weed pollens have been shown to affect AR and asthma issues in the Midwestern US, especially in the late summer and early fall season. Knowledge about pollen season lengths and patterns can help with management of allergic rhinitis and asthma.3,4,5
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research
Condition:   Allergy Intervention:   Sponsors:   Stallergenes Greer;   Monitoring Force Group Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Subcutaneous allergen immunotherapy (SCIT) is effective for allergic rhinitis, allergic conjunctivitis, and allergic asthma1. Local reactions are the most common adverse effect associated with SCIT1, though systemic reactions to SCIT (SCITSR) are the most serious adverse effect1. The rate of systemic reactions to SCIT with a conventional dosing schedule is reported to be 0.1-0.2% per injection.1,2 It is generally accepted that the potential benefits of SCIT for select atopic conditions outweigh this risk of SCITSR.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
Discussion Atopic dermatitis (AD) has a prevalence of 3-5% in the overall U.S. population but is increasing with an estimated 10-15% lifetime risk in childhood. It is even more common in children of color with a prevalence in African-American/black children of 17% and Hispanic children of 14%. Health care utilization data also appears to support more severe disease in children of color also. Atopic dermatitis or eczema is a common dermatological skin problem which characteristically is a pruritic, papular eruption with erythema. Like most papulosquamous eruptions it often occurs in intertrigenous areas in people with alle...
Source: PediatricEducation.org - Category: Pediatrics Authors: Tags: Uncategorized Source Type: news
AbstractAllergen immunotherapy (AIT) for allergic rhinitis (AR), asthma, and other allergic diseases has developed quickly. House dust mite (HDM),Artemisia (wormwood),Humulus japonicus (Japanese hop),Alternaria alternata, andCladosporium herbarum are the five most common inhalant allergens in China. AIT has been performed in China for over 60  years. With the support of the Chinese Medical Association (CMA) and the Chinese Medical Doctors Association (CMDA), the Chinese College of Allergy and Asthma (CCAA) was established in 2016 as a specialized branch of CDMA and is the main certification authority for AIT. Chinese ...
Source: Clinical Reviews in Allergy and Immunology - Category: Allergy & Immunology Source Type: research
AbstractPQ Grass represents an allergen ‐specific immunotherapy for pre‐seasonal treatment of patients with seasonal allergic rhinitis (or rhinoconjunctivitis) with or without mild‐to‐moderate bronchial asthma. It consists of a native pollen extract for 13 grass species, chemically modified with glutaraldehyde, and adsorbed tol‐tyrosine in a microcrystalline form with addition of the adjuvant Monophosphoryl Lipid A (MPL®). Previous non ‐clinical safety testing, including rat repeat dose toxicity in adult and juvenile animals, rat reproductive toxicity and rabbit local tolerance studies showed no safety find...
Source: Journal of Applied Toxicology - Category: Toxicology Authors: Tags: RESEARCH ARTICLE Source Type: research
More News: Allergy | Allergy & Immunology | Asthma | Hay Fever | Health | Japan Health